PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8747782-5	1995	CCK-8-induced muscle strip contraction was atropine and tetrodotoxin resistant, but was completely eliminated by devazepide.	Devazepide	113-123	cholecystokinin	Canis lupus familiaris	0-3	
8769975-8	1996	These studies demonstrate that L-364,718 has a dose dependent, inhibitory effect on basal, and OP-CCK-stimulated amylase secretion in a denervated autograft model.	Devazepide	31-40	cholecystokinin	Canis lupus familiaris	98-101	
8661821-8	1996	Group 1 dogs received an intravenous bolus of MK329, a specific CCK receptor antagonist, at 20 nmol/kg after a standard mixed meal; group 2 colonic TVF dogs received a meal and an intravenous bolus of PYY polyclonal antibody at 1 mg/kg.	Devazepide	46-51	cholecystokinin	Canis lupus familiaris	64-67	
8319843-4	1993	Nevertheless other CCK-related mechanisms may play an important role, since the administration of the highly specific CCK receptor antagonist MK-329 causes a marked reduction of the GRP-induced exocrine pancreatic secretion.	Devazepide	142-148	cholecystokinin	Canis lupus familiaris	19-22	
7926458-6	1994	CCK-8 infused intravenously (0.1-1 microgram.kg-1.h-1) dose dependently increased the occurrence of relaxations while it was reduced by the CCK-A receptor antagonist devazepide but not the CCK-B antagonist L365260, both administered intravenously in a dose range of 0.1-100 micrograms/kg.	Devazepide	166-176	cholecystokinin	Canis lupus familiaris	0-3	
7926458-8	1994	Both devazepide and L365260 (10 micrograms/kg) reduced the CCK-induced relaxations, but devazepide was more potent.	Devazepide	5-15	cholecystokinin	Canis lupus familiaris	59-62	
7910794-5	1994	Blockade of type A CCK receptors with MK-329 (75 micrograms/kg, i.v.)	Devazepide	38-44	cholecystokinin	Canis lupus familiaris	19-22	
8319843-4	1993	Nevertheless other CCK-related mechanisms may play an important role, since the administration of the highly specific CCK receptor antagonist MK-329 causes a marked reduction of the GRP-induced exocrine pancreatic secretion.	Devazepide	142-148	cholecystokinin	Canis lupus familiaris	118-121	
1438992-2	1992	L364718 at a dose of 1.0 mg/kg was used as a specific and potent CCK receptor blocker, and its effect on spontaneous interdigestive motility and plasma motilin release were examined.	Devazepide	0-7	cholecystokinin	Canis lupus familiaris	65-68	
1438992-4	1992	Whether the blocking effect of L364718 on CCK receptors was sufficient or not was verified by giving CCK-OP at a bolus dose of 10 ng/kg.	Devazepide	31-38	cholecystokinin	Canis lupus familiaris	42-45	
1438992-7	1992	On the other hand, the effect of CCK-OP was completely abolished by pretreatment with L364718.	Devazepide	86-93	cholecystokinin	Canis lupus familiaris	33-36	
2437283-0	1987	Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecystokinin receptor antagonist.	Devazepide	94-103	cholecystokinin	Canis lupus familiaris	116-131	
3441445-0	1987	L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs.	Devazepide	0-7	cholecystokinin	Canis lupus familiaris	15-18	
3441445-0	1987	L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs.	Devazepide	0-7	cholecystokinin	Canis lupus familiaris	62-65	
3441445-5	1987	This study demonstrates that L364718 acts as a potent antagonist of CCK"s action on pancreatic enzyme secretion and PP release in dogs and suggests that this agent might be a useful tool for studying the physiological role of CCK in conscious animals.	Devazepide	29-36	cholecystokinin	Canis lupus familiaris	68-71	
3441445-5	1987	This study demonstrates that L364718 acts as a potent antagonist of CCK"s action on pancreatic enzyme secretion and PP release in dogs and suggests that this agent might be a useful tool for studying the physiological role of CCK in conscious animals.	Devazepide	29-36	cholecystokinin	Canis lupus familiaris	226-229	
2135899-7	1990	Pretreatment with a highly selective CCK-receptor antagonist L-364 718 (1 mg/kg i.v.)	Devazepide	61-70	cholecystokinin	Canis lupus familiaris	37-40